Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCH014
MIFTS: 62

Schistosomiasis

Categories: Rare diseases, Infectious diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Schistosomiasis

About this section

MalaCards integrated aliases for Schistosomiasis:

Name: Schistosomiasis 12 76 53 55 3 15 73
Katayama Fever 53 73
Bilharzia 53 3
Schistosoma Mansoni Infection 53
Schistosomiasis Mansoni 73
Blood Fluke 53

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1395
ICD9CM 35 120.8
SNOMED-CT 68 187116001 187121003
Sources

Summaries for Schistosomiasis

About this section
NIH Rare Diseases : 53 Schistosomiasis is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. Infection occurs through contact with contaminated water. The parasite in its infective stages is called a cercaria. It swims freely in open bodies of water. On contact with humans, the parasite burrows into the skin, matures into another stage (schistosomula), then migrates to the lungs and liver, where it matures into the adult form. The adult worm then migrates to its preferred body part (bladder, rectum, intestines, liver, portal venous system (the veins that carry blood from the intestines to liver, spleen, lungs), depending on its species.  Schistosomiasis is common in many tropical and subtropical areas worldwide. It can be treated safely and effectively with praziquantel.

MalaCards based summary : Schistosomiasis, also known as katayama fever, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosomiasis is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Albendazole and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and spleen, and related phenotypes are homeostasis/metabolism and cellular

CDC : 3  

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves infection of the intestine, urinary tract, skin, liver and spleen caused by multiple species of the trematode fluke of the genus Schistosoma. The symptoms include fever, chills, nausea, abdominal pain, diarrhea, malaise, myalgia, liver and spleen enlargement, rash and hematuria.

Wikipedia : 76 Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms... more...

Sources

Related Diseases for Schistosomiasis

About this section

Diseases related to Schistosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 493)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 34.1 CD40LG IL13 IL4 IL5 STAT6
2 urinary schistosomiasis 33.5 IFNG IL13 IL4 IL5 RNASE3 STAT6
3 neuroschistosomiasis 32.9 CD79A IFNG
4 fascioliasis 31.2 ALB IFNG IL10
5 toxocariasis 31.0 CD40LG IGHE RNASE3
6 paragonimiasis 31.0 IL13 IL5 RNASE3
7 endomyocardial fibrosis 30.9 IL10 IL4 TNF
8 strongyloidiasis 30.8 CD79A IFNG IL13 IL5
9 portal hypertension 30.7 ALB F2 TNF
10 alpha chain disease 30.6 CD40LG CD79A
11 trichuriasis 30.5 IL10 IL13 TNF
12 appendicitis 30.5 ALB IL10 TNF
13 trichinosis 30.5 CD40LG IL4 IL5
14 eosinophilic pneumonia 30.4 IL13 IL5 RNASE3
15 tropical endomyocardial fibrosis 30.4 IL10 IL4 TNF
16 hepatitis b 30.4 ALB F2 IFNG TNF
17 plasmodium falciparum malaria 30.4 IFNG IL10 TNF
18 hypersplenism 30.3 ALB F2 IFNG
19 neuritis 30.3 IFNG IL4 TNF
20 granulomatous hepatitis 30.3 CD40LG CD79A IL4
21 diarrhea 30.1 ALB CD40LG CD79A TNF
22 buruli ulcer 30.1 CD40LG IFNG IL10 IL4
23 salmonellosis 30.0 ALB IFNG IFNGR1
24 viral hepatitis 30.0 ALB CD40LG F2 TNF
25 peritonitis 29.9 ALB F2 IL10 TNF
26 prostatitis 29.7 IL10 IL2 TNF
27 toxoplasmosis 29.6 CD40LG CD79A IFNG IL10 IL4 TNF
28 lymphadenitis 29.5 IFNG IFNGR1 IL10 TNF
29 meningitis 29.5 ALB CD40LG IFNG IL10 TNF
30 hepatitis e 29.4 ALB CD40LG F2 IFNG TNF
31 onchocerciasis 29.4 IL13 IL2 IL4 IL5 RNASE3
32 dermatitis 29.4 IFNG IGHE IL13 IL4 IL5 RNASE3
33 echinococcosis 29.3 CD40LG CD79A IFNG IL10 IL5 TNF
34 smallpox 29.3 IFNG IL2 TNF
35 pneumonia 29.0 CCL3 CD40LG IL10 IL13 IL5 TNF
36 filariasis 28.9 ALB IFNG IL10 IL2 IL5 TNF
37 clonorchiasis 28.9 CD79A IFNG IL10 IL2 TNF
38 typhoid fever 28.9 ALB F2 IFNG IFNGR1 TNF
39 leishmaniasis 28.8 IFNG IFNGR1 IL10 IL13 IL4 IL5
40 parasitic helminthiasis infectious disease 28.4 CD40LG CD79A IL10 IL13 IL4 IL5
41 paracoccidioidomycosis 28.2 IFNG IL10 IL2 IL4 IL5 TNF
42 chagas disease 28.2 CCL3 IFNG IL10 IL2 TNF
43 human immunodeficiency virus type 1 28.1 CCL3 IFNG IL10 IL2 TNF
44 trypanosomiasis 27.6 ALB CCL3 IFNG IL10 IL2 IL4
45 autoimmune disease 27.3 CD40LG CD79A IFNG IL10 IL2 IL4
46 pulmonary tuberculosis 26.8 CCL3 IFNG IFNGR1 IL10 IL2 IL4
47 acquired immunodeficiency syndrome 26.8 ALB CCL3 CD40LG CD79A IFNG IL10
48 asthma 26.0 CCL3 CD40LG CD79A F2 IFNG IGHE
49 malaria 25.1 ALB CCL3 CD40LG GAPDH IFNG IFNGR1
50 cercarial dermatitis 11.9

Graphical network of the top 20 diseases related to Schistosomiasis:



Diseases related to Schistosomiasis
Sources

Symptoms & Phenotypes for Schistosomiasis

About this section

MGI Mouse Phenotypes related to Schistosomiasis:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 F2 ALB IFNG CD40LG CD79A IFNGR1
2 cellular MP:0005384 10.31 IFNGR1 ALB CD40LG IFNG CD79A TNF
3 hematopoietic system MP:0005397 10.31 F2 IFNG CD40LG CD79A IFNGR1 LGMN
4 immune system MP:0005387 10.27 IFNGR1 F2 IFNG CD40LG CD79A LGMN
5 digestive/alimentary MP:0005381 10.22 F2 ALB IFNG IFNGR1 TNF IL5
6 endocrine/exocrine gland MP:0005379 10.21 IFNGR1 ALB CD40LG IFNG TNF STAT6
7 liver/biliary system MP:0005370 10.14 ALB IFNG CD79A IFNGR1 LGMN STAT6
8 integument MP:0010771 10.09 F2 CD40LG IFNG TNF STAT6 IL13
9 neoplasm MP:0002006 10.02 ALB IFNG CD79A IFNGR1 STAT6 TNF
10 reproductive system MP:0005389 9.9 IFNGR1 F2 IFNG CD40LG STAT6 TNF
11 no phenotypic analysis MP:0003012 9.87 CD79A IFNG TNF IL13 IL2 IL10
12 renal/urinary system MP:0005367 9.86 IFNGR1 ALB CD40LG IFNG CD79A LGMN
13 respiratory system MP:0005388 9.61 F2 IFNG IL5 STAT6 TNF IL2
14 skeleton MP:0005390 9.28 F2 CD40LG IFNG TNF LGMN IL13
Sources

Drugs & Therapeutics for Schistosomiasis

About this section

Drugs for Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54965-21-8 2082
2
Artemether Approved Phase 4 71963-77-4 119380 68911
3
Lumefantrine Approved Phase 4 82186-77-4 6437380
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55268-74-1 4891
6 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antifungal Agents Phase 4
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antimalarials Phase 4,Phase 2,Phase 3
10 Antimitotic Agents Phase 4,Phase 3,Not Applicable
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Not Applicable
13 Artemether-lumefantrine combination Phase 4
14 Artemisinine Phase 4,Phase 2,Phase 3
15 Artemisinins Phase 4,Phase 2,Phase 3
16
Zinc Approved, Investigational Phase 3 7440-66-6 23994
17
Artesunate Approved, Investigational Phase 2, Phase 3 88495-63-0 6917864 5464098
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 58-14-0 4993
19
Piperaquine Approved, Investigational Phase 3 4085-31-8 5079497
20
Sulfadoxine Approved, Investigational Phase 3,Phase 2 2447-57-6 17134
21
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
22
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
23
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
24
Adalimumab Approved Phase 3 331731-18-1 16219006
25
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
26
Tofacitinib Approved, Investigational Phase 3 477600-75-2
27
Iron Approved Phase 3,Not Applicable 7439-89-6 23925
28
Tranexamic Acid Approved Phase 3 1197-18-8 5526
29
Myrrh Approved, Nutraceutical Phase 3 9000-45-7
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3 59-30-3 6037
31
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 58-05-9 143 6006
32 Triclabendazole Investigational Phase 3 68786-66-3
33 Micronutrients Phase 3,Not Applicable
34 Trace Elements Phase 3,Not Applicable
35 Vitamins Phase 3,Not Applicable
36 Vaccines Phase 3,Phase 2,Phase 1
37 Folic Acid Antagonists Phase 2, Phase 3,Phase 3
38 Renal Agents Phase 2, Phase 3,Phase 3
39 Sulfalene Phase 2, Phase 3
40 Vitamin B Complex Phase 2, Phase 3,Phase 3
41 Fanasil, pyrimethamine drug combination Phase 3,Phase 2
42 Cardiac Glycosides Phase 3
43 Glycoside Hydrolase Inhibitors Phase 3
44 Hypoglycemic Agents Phase 3
45 Angiogenesis Inhibitors Phase 3,Phase 2
46 Angiogenesis Modulating Agents Phase 3,Phase 2
47 Anti-Inflammatory Agents Phase 3
48 glucocorticoids Phase 3
49 Hormone Antagonists Phase 3
50 Hormones Phase 3

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children Completed NCT01087099 Phase 4 Albendazole
5 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Not yet recruiting NCT02868385 Phase 4 4x Praziquantel;1x Praziquantel
6 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Not yet recruiting NCT02734186 Phase 4 Praziquantel
7 A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency Unknown status NCT02337569 Phase 3 NPC-02
8 Safety and Efficacy of Mirazid for Schistosomiasis Treatment Completed NCT01529710 Phase 3 Myrrh
9 Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium Completed NCT00870649 Phase 3
10 Schistosoma Haematobium Infections and Praziquantel Completed NCT01558336 Phase 3 praziquantel
11 Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis Completed NCT00510159 Phase 2, Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamin;Praziquantel
12 Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
13 Acarbose and Secondary Prevention After Coronary Stenting Completed NCT00221156 Phase 3 Acarbose
14 Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
15 A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). Completed NCT02480153 Phase 3
16 A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis Completed NCT02281552 Phase 3 Tofacitinib;Tofacitinib
17 Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan Completed NCT00661661 Phase 3 CP-690,550
18 The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium Recruiting NCT03133832 Phase 3 Companion Tablet
19 Haemorrhage Alleviation With Tranexamic Acid- Intestinal System Recruiting NCT01658124 Phase 3 Tranexamic Acid;Placebo
20 Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Recruiting NCT03443973 Phase 3 Gantenerumab;Placebo
21 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3 Crenezumab;Placebo
22 IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Active, not recruiting NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
23 CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Active, not recruiting NCT02670083 Phase 3 Crenezumab;Placebo
24 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Active, not recruiting NCT02706873 Phase 3 ABT-494 matching placebo;Methotrexate;Methotrexate matching placebo;ABT-494
25 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
26 Schistosoma Mansoni Morbidity in Children Aged 1-5 Years Completed NCT01901484 Phase 2 Praziquantel
27 S. Japonicum and Pregnancy Outcomes Completed NCT00486863 Phase 2 Praziquantel
28 Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions Completed NCT03041766 Phase 2 GLA-SE solution
29 Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents Completed NCT02178748 Phase 2
30 Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Completed NCT00864838 Phase 2 Acetazolamide;Brimonidine tartarate
31 An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Recruiting NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
32 A Study to Compare Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Active, not recruiting NCT02720523 Phase 2 Placebo;ABT-494
33 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
34 Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis Completed NCT01512277 Phase 1
35 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
36 Praziquantel-Pharmacokinetic Study Completed NCT01288872 Phase 1 Praziquantel
37 Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS Completed NCT02376582 Phase 1
38 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Recruiting NCT03110757 Phase 1
39 Controlled Human Infection for Vaccination Against Streptococcus Pyogenes Recruiting NCT03361163 Phase 1
40 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Unknown status NCT01869465 Not Applicable
41 Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Unknown status NCT01260012 Not Applicable
42 A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes Unknown status NCT01541631 Not Applicable Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
43 Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation Unknown status NCT00926315 Not Applicable calcitriol;Calcitriol
44 Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Completed NCT01424410
45 Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Completed NCT02144389 Not Applicable Praziquantel (PZQ)
46 Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso Completed NCT00463528
47 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
48 Urinary Schistosomiasis Infection Completed NCT00138450
49 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
50 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Completed NCT00463593

Search NIH Clinical Center for Schistosomiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Schistosomiasis

About this section
Sources

Anatomical Context for Schistosomiasis

About this section

MalaCards organs/tissues related to Schistosomiasis:

41
Liver, Skin, Spleen, Testes, Kidney, Lung, T Cells
Sources

Publications for Schistosomiasis

About this section

Articles related to Schistosomiasis:

(show top 50) (show all 2005)
# Title Authors Year
1
Schistosomiasis in immigrants, refugees and travellers in an Italian referral centre for tropical diseases. ( 29907162 )
2018
2
Dataset on usnic acid from <i>Cladonia substellata</i> Vainio (Lichen) schistosomiasis mansoni's vector control and environmental toxicity. ( 29876395 )
2018
3
Praziquantel for the treatment of schistosomiasis during human pregnancy. ( 29403101 )
2018
4
Schistosomiasis in a returning international traveler with cyclic fevers and diarrhea. ( 29449243 )
2018
5
18F-NaF PET/CT Finding in a Patient With Abdominal Discomfort After Schistosomiasis. ( 29356743 )
2018
6
Underestimation of the global burden of schistosomiasis. ( 29413041 )
2018
7
Eggs and Magnetism: New Approaches for Schistosomiasis Diagnosis. ( 29422443 )
2018
8
Urinary schistosomiasis presented as bladder malignancy with pulmonary metastases: a case report. ( 29962297 )
2018
9
The current epidemiological status of urogenital schistosomiasis among primary school pupils in Katsina State, Nigeria: An imperative for a scale up of water and sanitation initiative and mass administration of medicines with Praziquantel. ( 29979684 )
2018
10
Infection status and risk factors associated with urinary schistosomiasis among school-going children in the Ndumo area of uMkhanyakude District in KwaZulu-Natal, South Africa two years post-treatment. ( 29679769 )
2018
11
Gastric fundus splenosis with hemangioma masquerading as a gastrointestinal stromal tumor in a patient with schistosomiasis and cirrhosis who underwent splenectomy: A case report and literature review. ( 29979450 )
2018
12
Schistosomiasis as a cause of acute cholecystitis. ( 29968897 )
2018
13
The use of gold nanorods as a new vaccine platform against schistosomiasis. ( 29428201 )
2018
14
Estimating the prevalence of schistosomiasis japonica in China: a serological approach. ( 29961423 )
2018
15
The epidemiology of schistosomiasis in Lango region Uganda 60 years after Schwetz 1951: Can schistosomiasis be eliminated through mass drug administration without other supportive control measures? ( 29935144 )
2018
16
Hepatic schistosomiasis with massive splenomegaly: a case report and literature review. ( 29562382 )
2018
17
Defining the Pathways of Urogenital Schistosomiasis-Associated Urothelial Carcinogenesis through Transgenic and Bladder Wall Egg Injection Models. ( 28889378 )
2018
18
Prevalence of schistosomiasis mansoni in indigenous Maxakali villages, Minas Gerais, Brazil. ( 29972467 )
2018
19
A rare cause of diarrhea in the occident: A case of colonic schistosomiasis. ( 29887404 )
2018
20
Capacity gaps in health facilities for case management of intestinal schistosomiasis and soil-transmitted helminthiasis in Burundi. ( 29970181 )
2018
21
Low incidence of helminth infections (schistosomiasis, strongyloidiasis, filariasis, toxocariasis) among Dutch long-term travelers: A prospective study, 2008-2011. ( 29847574 )
2018
22
Schistosomiasis detected during appendectomy. ( 29976471 )
2018
23
Could diet composition modulate pathological outcomes in schistosomiasis mansoni? A systematic review of in vivo preclinical evidence. ( 29400268 )
2018
24
Impact of Mothers' Schistosomiasis Status During Gestation on Children's IgG Antibody Responses to Routine Vaccines 2a88Years Later and Anti-Schistosome and Anti-Malarial Responses by Neonates in Western Kenya. ( 29967622 )
2018
25
Schistosomiasis in Africa: Improving strategies for long-term and sustainable morbidity control. ( 29953454 )
2018
26
The Spatial-Temporal Trend Analysis of Schistosomiasis from 1997 to 2010 in Anhui Province, Eastern China. ( 29436347 )
2018
27
Post-transplant liver graft schistosomiasis in a migrant from Sub-Saharan Africa, Italy 2017. ( 29890019 )
2018
28
Field and laboratory comparative evaluation of a LAMP assay for the diagnosis of urogenital schistosomiasis in Cubal, Central Angola. ( 29920859 )
2018
29
Compounds from African Medicinal Plants with Activities Against Selected Parasitic Diseases: Schistosomiasis, Trypanosomiasis and Leishmaniasis. ( 29744736 )
2018
30
Evaluation of transient elastography in assessing liver fibrosis in patients with advanced schistosomiasis japonica. ( 29355611 )
2018
31
Expanding molecular diagnostics of helminthiasis: Piloting use of the GPLN platform for surveillance of soil transmitted helminthiasis and schistosomiasis in Ghana. ( 29370166 )
2018
32
Historical perspective: Revisiting the St. Lucia Project, a multi-year comparison trial of schistosomiasis control strategies. ( 29385131 )
2018
33
Quality of life and quality-adjusted life years of chronic schistosomiasis mansoni patients in Brazil in 2015. ( 29945168 )
2018
34
Arsenicosis in bladder pathology and schistosomiasis in Eggua, Nigeria. ( 29868729 )
2018
35
An Integrated Approach to Control Soil-Transmitted Helminthiasis, Schistosomiasis, Intestinal Protozoa Infection, and Diarrhea: Protocol for a Cluster Randomized Trial. ( 29895511 )
2018
36
Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules. ( 29401734 )
2018
37
Paediatric schistosomiasis: What we know and what we need to know. ( 29420537 )
2018
38
Knowledge, attitudes and practices on Schistosomiasis in sub-Saharan Africa: a systematic review. ( 29347919 )
2018
39
Study of diagnostic accuracy of Helmintex, Kato-Katz, and POC-CCA methods for diagnosing intestinal schistosomiasis in Candeal, a low intensity transmission area in northeastern Brazil. ( 29518081 )
2018
40
Intestinal Schistosomiasis: A Rare Cause of Abdominal Pain and Weight loss. ( 29560299 )
2018
41
Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial. ( 29436337 )
2018
42
Evaluation of diagnostic methods for the detection of intestinal schistosomiasis in endemic areas with low parasite loads: Saline gradient, Helmintex, Kato-Katz and rapid urine test. ( 29470516 )
2018
43
Under diagnosis of intestinal schistosomiasis in a referral hospital, North Ethiopia. ( 29661251 )
2018
44
Mass drug administration and the sustainable control of schistosomiasis: Community health workers are vital for global elimination efforts. ( 29128644 )
2018
45
Praziquantel Targets M1 Macrophages and Ameliorates Splenomegaly in Chronic Schistosomiasis. ( 29061758 )
2018
46
Underestimation of the global burden of schistosomiasis - Authors' reply. ( 29413043 )
2018
47
Effectiveness of vinpocetine and isosorbide-5-mononitrate on experimental schistosomiasis mansoni: Biochemical and immunohistochemical study. ( 29963994 )
2018
48
Surveillance of intestinal schistosomiasis during control: a comparison of four diagnostic tests across five Ugandan primary schools in the Lake Albert region. ( 29560841 )
2018
49
Schistosomiasis and Strongyloidiasis Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381575 )
2018
50
Comparison of three data mining models for prediction of advanced schistosomiasis prognosis in the Hubei province. ( 29447165 )
2018
Sources

Variations for Schistosomiasis

About this section
Sources

Expression for Schistosomiasis

About this section
Search GEO for disease gene expression data for Schistosomiasis.
Sources

Pathways for Schistosomiasis

About this section

Pathways related to Schistosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.07 CCL3 CD40LG CD79A IFNG IFNGR1 IGHE
2
PEDF Induced Signaling 64
Show member pathways
 13.73 CCL3 CD40LG F2 IFNG IFNGR1 IL10
3
TGF-Beta Pathway 64
Show member pathways
 13.57 CCL3 F2 IFNG IFNGR1 IL10 IL13
4
Akt Signaling 64
Show member pathways
 13.47 CCL3 CD40LG IL10 IL13 IL2 IL4
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.37 CCL3 CD40LG IFNG IFNGR1 IGHE IL10
6
PAK Pathway 64
Show member pathways
 13.34 CCL3 CD40LG IL10 IL13 IL2 IL4
7
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13.04 CCL3 IFNG IFNGR1 IL10 IL2 TNF
8
Pathways in cancer 37
12.9 IFNG IFNGR1 IL13 IL2 IL4 IL5
9
Allograft rejection 1 37
Show member pathways
 12.85 CD40LG IFNG IFNGR1 IL10 IL13 IL2
10
IL-2 Pathway 64
Show member pathways
 12.84 CD79A IFNG IFNGR1 IL2 IL4 TNF
11
Influenza A 37
Show member pathways
 12.84 IFNG IFNGR1 IL13 IL2 IL4 TNF
12
Immune response IL-23 signaling pathway 22
Show member pathways
 12.66 F2 IFNG IL10 IL2 STAT6 TNF
13
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.66 CD79A IGHE IL13 IL4 IL5 TNF
14
NF-kappaB Signaling 4
12.65 CD40LG CD79A IFNG IL10 IL2 IL4
15
Regulation of IFNA signaling 66
Show member pathways
 12.65 IFNG IFNGR1 IL10 IL13 IL2 IL4
16
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.56 IFNG IFNGR1 IL2 IL4 TNF
17
T cell receptor signaling pathway 37
Show member pathways
 12.53 CD40LG IFNG IL10 IL2 IL4 IL5
18
Folate Metabolism 1
Show member pathways
 12.43 ALB F2 IFNG IL2 IL4 TNF
19
IL-17 Family Signaling Pathways 65
Show member pathways
 12.4 IFNG IL13 IL4 IL5 TNF
20
Th17 cell differentiation 37
Show member pathways
 12.4 IFNG IFNGR1 IL10 IL13 IL2 IL4
21
Toxoplasmosis 37
Show member pathways
 12.36 CD40LG IFNG IFNGR1 IL10 IL4 TNF
22
Th1 Differentiation Pathway 65
Show member pathways
 12.33 IFNG IFNGR1 IL10 IL2 TNF
23
Tuberculosis 37
12.26 IFNG IFNGR1 IL10 TNF
24
Necroptosis 37
Show member pathways
 12.24 IFNG IFNGR1 STAT6 TNF
25
Bacterial infections in CF airways 22
Show member pathways
 12.22 IFNG IFNGR1 IL4 TNF
26
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.21 GAPDH IL10 IL13 TNF
27
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.16 CCL3 IFNG IFNGR1 IL10 IL13 IL2
28
Interleukin-4 and 13 signaling 66
12.09 IGHE IL10 IL13 IL4 STAT6 TNF
29
IL12-mediated signaling events 1
Show member pathways
 12.07 CCL3 IFNG IL2 IL4 STAT6
30
Spinal Cord Injury 1
12.06 IFNG IL2 IL4 TNF
31
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.04 CD79A IFNG IL10 IL2 IL4 IL5
32
Jak-Stat Signaling Pathway 67
11.98 IFNG IFNGR1 IL10 IL2 STAT6
33
Glucocorticoid receptor regulatory network 1
11.91 IFNG IL13 IL2 IL4 IL5
34
Rheumatoid arthritis 37
11.85 CCL3 IFNG TNF
35
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.85 CD40LG IFNG IL2 IL4 IL5 TNF
36
Dendritic Cells Developmental Lineage Pathway 65
11.83 IFNG IL10 IL2 TNF
37
Salmonella infection (KEGG) 37
11.82 CCL3 IFNG IFNGR1
38
Lung fibrosis 1
11.78 CCL3 IL13 IL4 IL5 TNF
39
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.74 CD40LG IFNG IL2 TNF
40
IL4-mediated signaling events 1
11.73 CD40LG IGHE IL10 IL4 IL5 STAT6
41
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.67 IFNG IL2 TNF
42
Interleukin-10 signaling 66
11.66 CCL3 IL10 IL13 IL4 TNF
43
Malaria 37
11.62 CD40LG IFNG IL10 TNF
44
Photodynamic therapy-induced AP-1 survival signaling. 1
11.59 IFNG IL2 TNF
45
Cellular Transformation by HTLV1 64
Show member pathways
 11.58 IFNG IFNGR1 TNF
46
Aryl Hydrocarbon Receptor Pathway 1
11.55 IFNG IL2 TNF
47
Innate Lymphoid Cell Differentiation Pathways 65
11.46 CCL3 IFNG IL10 IL13 IL2 IL4
48
Inflammatory Response Pathway 1
11.44 CD40LG IFNG IL2 IL4 IL5
49
Development and heterogeneity of the ILC family 1
11.41 IFNG IL13 IL4 IL5 TNF
50
African trypanosomiasis 37
11.4 IFNG IL10 TNF
Sources

GO Terms for Schistosomiasis

About this section

Cellular components related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 ALB CCL3 CD40LG F2 IFNG IL10
2 external side of plasma membrane GO:0009897 9.63 CD40LG CD79A F2 IGHE IL13 TNF
3 blood microparticle GO:0072562 9.56 ALB F2 IGHE SERPINF2
4 extracellular region GO:0005576 9.5 ALB CCL3 CD40LG F2 IFNG IGHE

Biological processes related to Schistosomiasis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.94 CCL3 IFNG LGMN TNF
2 defense response to bacterium GO:0042742 9.93 IGHE IL10 RNASE3 TNF
3 positive regulation of protein phosphorylation GO:0001934 9.87 F2 IFNG IL2 TNF
4 inflammatory response GO:0006954 9.85 CCL3 CD40LG IL10 IL13 IL5 TNF
5 immune response GO:0006955 9.85 CCL3 CD40LG IFNG IGHE IL10 IL13
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IFNG IL13 IL2
7 positive regulation of T cell proliferation GO:0042102 9.79 CD40LG IL2 IL4
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 IL13 SERPINF2 TNF
9 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.77 F2 GAPDH RNASE3
10 negative regulation of endothelial cell apoptotic process GO:2000352 9.71 IL10 IL13 IL4
11 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.66 IFNG IFNGR1
12 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
13 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL2 IL5
14 positive regulation of podosome assembly GO:0071803 9.65 IL5 TNF
15 regulation of signaling receptor activity GO:0010469 9.65 CCL3 CD40LG F2 IFNG IL10 IL13
16 negative regulation of fibrinolysis GO:0051918 9.64 F2 SERPINF2
17 positive regulation of isotype switching to IgG isotypes GO:0048304 9.63 IL2 IL4
18 B cell proliferation GO:0042100 9.63 CD40LG CD79A IL10
19 endothelial cell apoptotic process GO:0072577 9.62 IL10 TNF
20 B cell differentiation GO:0030183 9.62 CD40LG CD79A IL10 IL4
21 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 IL4
22 positive regulation of cytokine secretion GO:0050715 9.61 GAPDH IL10 TNF
23 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
24 type 2 immune response GO:0042092 9.58 IL10 IL4
25 regulation of immunoglobulin secretion GO:0051023 9.56 CD40LG TNF
26 positive regulation of B cell proliferation GO:0030890 9.56 IL13 IL2 IL4 IL5
27 regulation of isotype switching GO:0045191 9.55 IL10 IL4
28 positive regulation of isotype switching to IgE isotypes GO:0048295 9.52 IL4 STAT6
29 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
31 negative regulation of complement-dependent cytotoxicity GO:1903660 9.48 IL13 IL4
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
33 cytokine-mediated signaling pathway GO:0019221 9.32 CCL3 IFNGR1 IGHE IL10 IL13 IL2

Molecular functions related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 F2 IL10 IL2 IL4 IL5
2 cytokine activity GO:0005125 9.28 CCL3 CD40LG IFNG IL10 IL13 IL2
Sources

Sources for Schistosomiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....